🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Long awaited practice-changing results from ph 3 CM8HW now out in The Lancet. Nivo/ipi sign better than nivo mono in dMMR mCRC Sara Lonardi Bristol Myers Squibb #GI25 thelancet.com/journals/lance…

Myriam Chalabi Dr Amol Akhade Udhayvir Grewal ASCO LARVOL M. Bolton OncoAlert Really hoping COMMIT can help us answer this (yes, we’ll be left with cross trial comparison but hopefully it will shed some light on this subset of early progression).

Tiragolumab in combination with atezolizumab + bevacizumab in advanced or metastatic HCC The Lancet Oncology doi.org/10.1016/S1470-… 🔎 MORPHEUS-Liver phs 1b–2, 59 pts 👉ORR 43% vs 11% 👉mPFS 12.3 vs 4.2 mo 👉mOS 28.9 vs 15.1 mo 🧐anti-TIGIT looks really promising ESMO - Eur. Oncology EASL Education

Congrats Alison Schram and Alexander Drilon MD on leading this great work supporting recent accelerated approval for zenocotuzumab in NRG1 fusion+ pancreas and lung cancers! nejm.org/doi/full/10.10…

My time in industry convinced me of the importance of basic, government funded science research. It was crazy how much of the stuff we did was based directly on academic research that in-and-of-itself would have been too risky and/or too low-return for the company to do

📢 New research out today on #TILTherapy for GI cancers ❓Can neoantigen-specific tumor-infiltrating lymphocytes (TILs) improve immunotherapy for gastrointestinal cancers? ➡️ In this study, published in Nature Medicine, Lowery, et al. National Cancer Institute found that expanding TILs that

Amazing #BREAKWATER data - especially with 72% access to BRAFi in SOC arm. Great start to #ASCO(GI?)25!

Continued PFS2 benefit for nivo/ipi over nivo in MSI-H/dMMR CRC in #CM8HW. Curves flattening out - seems very likely we are curing more patients here! #ASCO25

DLL3 has arrived and hopefully here to stay in extrapulmonary NECs. Promising activity for DLL3-CD3 T cell engager obrixtamig irrespective of primary site, high IHC expression (>50%) appears to be required for response. Will this be needed for other agents in this space? #ASCO25

Thor Halfdanarson presenting early data on alpha NET therapy #ASCO25 with discussion by Heloisa Soares MD Emerging promising therapy in well-differentiated NET Neuroendocrine Cancer UK #NotJustNECancer Manchester Cancer Research Centre

Posters at #ASCO25 are starting now! Medical oncologist Rohit Thummalapalli will present a study that evaluated delta-like ligand 3 as an emerging target in gastroenteropancreatic neuroendocrine neoplasms. Memorial Sloan Kettering Cancer Center ASCO Learn more: bit.ly/3Fy3J5N

More evidence of potential application for testing DLL3 expression in GEP NENs Rohit Thummalapalli following oral presentation by Jaume Capdevila yesterday ASCO #ASCO2025 Neuroendocrine Cancer UK #NotJustNECancer

Impressive activity for LBL-024 PD-L1/4-1BB bispecific in epNEC with randomized P3 in combination with first line EP planned. And great discussion by Guillem Argiles Memorial Sloan Kettering Cancer Center! #ASCO25

Come on #ASCO25, this 💯 should have been a plenary! 7% improvement in 8-yr OS w exercise in adjuvant colon ca, greater than benefit for adding oxali to 5-FU (5% at 10 yrs in MOSAIC). Exercise = $ effective, ~0 tox, & gives pts sense of empowerment. Congrats Chris Booth et al!

The remarkable benefit of exercise was just extended to improved survival after cancer in a randomized trial NEJM #ASCO25 nejm.org/doi/full/10.10…

🚨 New research from ASCO: A clinical trial led by Yelena Y. Janjigian MD, Chief of Gastrointestinal Medical Oncology at MSK, has demonstrated a powerful new approach to help prevent cancer from coming back after treatment for #stomachcancer and #cancer of the lower portion of the

!!! Validates a number of retrospective studies in which controlling for socioeconomic status was challenging, potentially major implications across many ICI-treated cancer types… #ASCO25

Striking activity with ABBV-706 SEZ6 ADC in high grade neuroendocrine cancer (NECs) where active therapies are urgently needed. Thank you to the patients and their families. Alissa Cooper, MD #LCSM

Great review of a rapidly evolving field Nicholas Hornstein!

🧬Genomic mutations in GI neuroendocrine carcinoma ESMO - Eur. Oncology GI Oncology ❗️13.4% is KRAS mutant ➡️ worse prognosis ❓RAS inhibitors in future? 👉esmogastro.org/article/S2949-… OncoAlert Thor Halfdanarson #cancer #oncology #MedX